ClinicalTrials.gg

Program

pociredir

Also written as “Pociredir”, “Pociredir oral capsule(s)” and “FTX-6058 - Two Dosing Periods”.

Its studies are mostly in Anemia, Sickle Cell, led by Fulcrum Therapeutics.

Furthest: phase 2, since Jan 28, 20264 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fulcrum Therapeutics40 open or runningphase 2since Jan 28, 2026Oct 5, 2020none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 5, 2020First study: phase 1 study in Anemia, Sickle CellFirst studyNCT04586985 · 109 enrolled · United States
  2. Dec 14, 2021Phase 1 study in Anemia, Sickle CellNCT05169580 · 45 enrolled · United States, Nigeria, South Africa
  3. Jan 28, 2026Phase 2 study in Anemia, Sickle CellPhase 2 reachedNCT07401823 · 1 enrolled · United States
  4. Feb 18, 2026Phase 1 study in Anemia, Sickle CellNCT07431398 · 13 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07431398Anemia, Sickle Cell · United States1TerminatedJun 1, 202613
NCT07401823Anemia, Sickle Cell · United States2TerminatedJun 4, 20261
NCT05169580Anemia, Sickle Cell · United States, Nigeria, South Africa1CompletedJan 20, 202645
NCT04586985Anemia, Sickle Cell · United States1CompletedNov 15, 2022109

How it is read

Names in the registry

  • “Pociredir”, 2 entries
  • “Pociredir oral capsule(s)”, 1 entry
  • “FTX-6058 - Two Dosing Periods”, 1 entry
  • “FTX-6058 / Midazolam Syrup”, 1 entry

Codes read as this program: FTX6058.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.